Pharmaceutical & Biotech News and Insights

Millennium to become Takeda Oncology
Millennium, a Massachusetts based company that was purchased by Takeda in 2008, will soon become Takeda Oncology. The rebranding of the iconic biotech and an ... 
Read More


Merck to buy Cubist
As part of a plan to focus on its most promising businesses, Merck & Co. has entered an agreement to buy Cubist Pharmaceuticals. The cost ... 
Read More


Dendreon Files for Bankruptcy
Despite numerous cost cutting measures, Dendreon has filed for Chapter 11 bankruptcy protection. It wasn't too long ago that things looked promising for the company ... 
Read More


Employee Numbers at Top 10 Pharma Companies
With so many patents expiring in 2012, it was not unexpected that the ten largest big pharma companies would have fewer employees by the end ... 
Read More


Shire’s CFO is Heading to Severn Trent
Days after the news that AbbVie deal with Shire would not be moving forward, news has come that Shire's interim CFO, James Bowling, will be ... 
Read More


AstraZeneca Photo-sharing Campaign to Help Fight Breast Cancer
October is Breast cancer awareness month. Yearly recognition of the deadly disease began in 1985 when drug manufacturer AstraZeneca encouraged women to have yearly mammograms. ... 
Read More


Roche's Perjeta is helping Breast Cancer Patients Live Longer
According to newly released results at the European Society for Medical Oncology, Roche's Perjeta's is lengthening the life expectancy of patients with HER2-positive breast cancer ... 
Read More


2015 Will Bring Changes for J&J Pension Benefits
In an effort to cut costs, J&J has announced that starting January 1, 2015 the company will reduce the pension benefits it offers to newly ... 
Read More


Release of generic form of Nexium is delayed
With sales of AstraZeneca's Nexium bringing in over $2 billion in US sales last year, there are several generics makers who are ready to enter ... 
Read More


Questions about Biosimilars
Recent inquires to the FDA have raised more questions about whether biosimilars should keep the same name as the branded biotech drugs. Doctor's state if ... 
Read More


« prev - page 1 of 3 - next »